Share price close 16 Nov 2026
Quarterly or annual report filed
Quarterly or annual report filed
In one paragraph
Baxter International reported revenue of $11.2 billion for fiscal year 2025 (the twelve months to 31 Dec 2025), up 5.7% from fiscal 2024. Net income was −$957 million and diluted earnings per share −$1.87.
In its latest reported quarter, the third quarter of fiscal 2026 (the three months to 30 Sep 2026), revenue was $2.98 billion, up 5.0% from a year earlier.
Figures from Baxter International's annual and quarterly reports, compiled and checked by AapWire. Latest report filed 29 Oct 2026.
Against Health Care
Among the sector's S&P 500 members with the figure; the longer the bar, the better placed. Debt and P/E rank lower first.
Fiscal 2025 against fiscal 2024; bars show the last 10 fiscal years; net debt is borrowings and operating lease liabilities less cash and short-term investments at the year end.
| Segment | Revenue | Share | Change |
|---|---|---|---|
| Medical Products & Therapies (earlier basis) | $5.30B | 47% | +1.8% |
| Healthcare Systems & Technologies | $3.07B | 27% | +4.1% |
| Pharmaceuticals | $2.49B | 22% | +3.4% |
| Other (earlier basis) | $381.0M | 3.4% | +469% |
Baxter International beside the other S&P 500 members in Health Care Equipment, by market value.
| Company | Market value | Day | 1 year | Revenue growth | Net margin | P/E |
|---|---|---|---|---|---|---|
| $13.30B | +0.3% | +38.0% | +5.3% | −6.2% | — | |
| $188.1B | +1.2% | −15.8% | +10.0% | 9.7% | 40.0 | |
| Intuitive SurgicalISRG | $152.6B | +0.8% | −22.5% | +20.5% | 25.5% | 51.6 |
| $63.86B | +0.3% | −57.4% | +8.9% | 16.6% | 18.2 | |
| $61.47B | +1.3% | +25.2% | +13.4% | 15.3% | 60.2 | |
| $59.14B | +1.1% | +44.4% | −2.6% | 4.5% | 62.9 | |
| $55.78B | +0.9% | −1.3% | +11.9% | 25.4% | 47.2 |
Market value and moves at the latest close. Revenue growth compares the last twelve months with the twelve before; net margin and P/E over the last twelve months; P/E is left blank where earnings are negative.
Fiscal years, as the company cuts its revenue in its annual reports; the change on a year under each figure. A change is left out from a loss, from a sliver of revenue, or across a change in how the company reports.
| Revenue | FY 2022 | FY 2023 | FY 2024 | FY 2025 |
|---|---|---|---|---|
| Medical Products & Therapies (earlier basis) | $4.82B | $5.01B+4.1% | $5.21B+3.9% | $5.30B+1.8% |
| Healthcare Systems & Technologies | $2.94B | $3.01B+2.5% | $2.95B−2.1% | $3.07B+4.1% |
| Pharmaceuticals | $2.13B | $2.25B+5.8% | $2.41B+7.2% | $2.49B+3.4% |
| Other (earlier basis) | $177.0M | $87.00M−50.8% | $67.00M−23.0% | $381.0M+469% |
| Total revenue | $10.06B | $10.36B | $10.64B | $11.24B |
| Revenue | FY 2021 | FY 2022 | FY 2023 | FY 2024 | FY 2025 |
|---|---|---|---|---|---|
| United States | $4.94B | $5.77B+16.8% | $5.80B+0.6% | $5.85B+0.8% | $6.12B+4.6% |
| International | $7.21B | $4.29B−40.5% | $4.56B+6.3% | $4.79B+5.0% | $5.12B+7.0% |
| Total revenue | $12.15B | $10.06B | $10.36B | $10.64B | $11.24B |
Fiscal years, the latest ending 31 Dec 2025. Amounts in USD. On a narrow screen the table opens on the latest year and scrolls back.
| Period | FY 2016 | FY 2017 | FY 2018 | FY 2019 | FY 2020 | FY 2021 | FY 2022 | FY 2023 | FY 2024 | FY 2025 |
|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | $10.16B | $10.58B | $11.10B | $11.36B | $11.67B | $12.15B | $10.06B | $10.36B | $10.64B | $11.24B |
| Revenue growth | +2.0% | +4.1% | +4.9% | +2.4% | +2.7% | +4.1% | −17.2% | +3.0% | +2.7% | +5.7% |
| Gross profit | $4.12B | $4.47B | $4.76B | $4.76B | $4.59B | $4.72B | $3.55B | $4.15B | $3.98B | $3.38B |
| Operating income | $745.0M | $1.29B | $1.58B | $1.77B | $1.62B | $1.35B | −$2.85B | $707.0M | $14.00M | −$308.0M |
| Net income | $4.96B | $602.0M | $1.55B | $1.00B | $1.10B | $1.28B | −$2.43B | $2.66B | −$649.0M | −$957.0M |
| Diluted EPS | $9.01 | $1.08 | $2.83 | $1.93 | $2.13 | $2.53 | −$4.83 | $5.23 | −$1.27 | −$1.87 |
| Gross margin | 40.5% | 42.3% | 42.9% | 41.9% | 39.3% | 38.9% | 35.3% | 40.1% | 37.5% | 30.1% |
| Operating margin | 7.3% | 12.2% | 14.3% | 15.6% | 13.8% | 11.1% | −28.3% | 6.8% | 0.1% | −2.7% |
| Net margin | 48.9% | 5.7% | 13.9% | 8.8% | 9.4% | 10.6% | −24.2% | 25.6% | −6.1% | −8.5% |
| Period | FY 2016 | FY 2017 | FY 2018 | FY 2019 | FY 2020 | FY 2021 | FY 2022 | FY 2023 | FY 2024 | FY 2025 |
|---|---|---|---|---|---|---|---|---|---|---|
| Operating cash flow | $1.65B | $1.71B | $2.02B | $2.10B | $1.87B | $2.22B | $1.21B | $1.73B | $1.02B | $845.0M |
| Capital expenditure | $719.0M | $616.0M | $659.0M | $696.0M | $709.0M | $691.0M | $377.0M | $432.0M | $446.0M | $513.0M |
| Free cash flow | $935.0M | $1.10B | $1.36B | $1.41B | $1.16B | $1.53B | $834.0M | $1.29B | $573.0M | $332.0M |
| Period | FY 2016 | FY 2017 | FY 2018 | FY 2019 | FY 2020 | FY 2021 | FY 2022 | FY 2023 | FY 2024 | FY 2025 |
|---|---|---|---|---|---|---|---|---|---|---|
| Cash and equivalents | $2.80B | $3.39B | $1.84B | $3.33B | $3.73B | $2.95B | $1.72B | $3.08B | $1.76B | $1.97B |
| Total debt | $2.78B | $3.51B | $3.48B | $5.96B | $6.80B | $18.31B | $17.20B | $14.11B | $13.45B | $9.78B |
| Shareholders' equity | $8.29B | $9.12B | $7.84B | $7.88B | $8.69B | $9.08B | $5.83B | $8.40B | $6.96B | $6.13B |
| Diluted shares | 551M | 555M | 546M | 519M | 517M | 508M | 504M | 508M | 510M | 513M |
| Dividends per share | $0.51 | $0.61 | $0.73 | $0.85 | $0.95 | $1.08 | $1.15 | $1.16 | $1.04 | $0.52 |
The last eight fiscal quarters, the latest ending 30 Sep 2026. Year-on-year growth compares the same quarter of the previous fiscal year.
| Period | Q4 FY2024 | Q1 FY2025 | Q2 FY2025 | Q3 FY2025 | Q4 FY2025 | Q1 FY2026 | Q2 FY2026 | Q3 FY2026 |
|---|---|---|---|---|---|---|---|---|
| Revenue | $2.75B | $2.63B | $2.81B | $2.83B | $2.97B | $2.70B | $2.96B | $2.98B |
| Revenue, year on year | +0.9% | +5.4% | +4.3% | +5.0% | +8.0% | +2.9% | +5.3% | +5.0% |
| Gross margin | 34.8% | 32.8% | 35.3% | 33.5% | 19.4% | 33.0% | 34.9% | 33.4% |
| Operating income | −$435.0M | $58.00M | $191.0M | $172.0M | −$729.0M | $66.00M | $217.0M | $225.0M |
| Net income | −$512.0M | $126.0M | $91.00M | −$46.00M | −$1.13B | −$15.00M | $126.0M | $294.0M |
| Diluted EPS | −$1.00 | $0.25 | $0.18 | −$0.09 | −$2.20 | −$0.03 | $0.24 | $0.57 |
| Free cash flow | $356.0M | −$315.0M | $77.00M | $126.0M | $444.0M | $76.00M | $169.0M | $448.0M |
The operating figures Baxter International reports beside its statements, then its revenue by product, segment and region, latest period first. Each links to its full history.
| KPI | Latest | Period | Change on a year | Recent periods |
|---|---|---|---|---|
| Infusion Therapies & Platforms revenue | $1.8B | quarter to 30 Sep 2026 | up 5.3% | |
| Infusion Therapies & Technologies revenue | $981.0M | quarter to 31 Mar 2026 | down 1.3% | |
| Care & Connectivity Solutions revenue | $498.0M | quarter to 30 Sep 2026 | up 5.3% | |
| Advanced Surgery revenue | $342.0M | quarter to 30 Sep 2026 | up 11.8% | |
| Drug Compounding revenue | $320.0M | quarter to 31 Mar 2026 | up 30.1% | |
| Front Line Care revenue | $308.0M | quarter to 30 Sep 2026 | up 2.7% | |
| Injectables & Anesthesia revenue | $301.0M | quarter to 31 Mar 2026 | down 10.1% | |
| Medical Products & Therapies revenue | $2.1B | quarter to 30 Sep 2026 | up 6.3% | |
| Healthcare Systems & Technologies revenue | $806.0M | quarter to 30 Sep 2026 | up 4.3% | |
| Pharmaceuticals revenue | $621.0M | quarter to 31 Mar 2026 | up 6.9% | |
| United States revenue | $1.6B | quarter to 30 Sep 2026 | up 3.3% | |
| International revenue | $1.4B | quarter to 30 Sep 2026 | up 7.0% |
Each period is read from the report the company filed and checked against accounting identities before it is shown; a figure that does not pass is left blank rather than estimated. Free cash flow is operating cash flow less capital expenditure. Fiscal years follow the company's own calendar. See data and methodology.
The same figures as plain text and JSON.
$11.2 billion for fiscal year 2025 (the twelve months to 31 Dec 2025), as reported in its annual report.
−$957 million for fiscal year 2025 (the twelve months to 31 Dec 2025).
−$1.87 for fiscal year 2025 (the twelve months to 31 Dec 2025).
30.1% for fiscal year 2025 (the twelve months to 31 Dec 2025): gross profit divided by revenue.
−2.7% for fiscal year 2025 (the twelve months to 31 Dec 2025): operating income divided by revenue.
$332 million for fiscal year 2025 (the twelve months to 31 Dec 2025): operating cash flow less capital expenditure.
In fiscal 2025, by segment: Medical Products & Therapies (earlier basis) $5.30B (47%), Healthcare Systems & Technologies $3.07B (27%), Pharmaceuticals $2.49B (22%), Other (earlier basis) $381.0M (3.4%), out of $11.24B in all, as stated in its annual report.
In the terminal